💊 Thuốc A-Z 🧬 Đích tác dụng 🛠 Công cụ 📚 Hướng dẫn
Tất cả thuốc Phân loại thuốc Lĩnh vực điều trị Tác dụng phụ
Hướng dẫn Từ điển thuật ngữ Dòng thời gian
So sánh Hành trình của thuốc Các họ thuốc
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Tasimelteon

CHEMBL2103822 Phase 4 Đã phê duyệt Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
245.3 g/mol
LogP
2.2
Phase
4

Tasimelteon is a selective melatonin receptor agonist (MT1 and MT2) approved for the treatment of non-24-hour sleep-wake disorder, a circadian rhythm disorder particularly prevalent in totally blind individuals without light perception. It synchronizes the circadian clock by mimicking the endogenous action of melatonin on suprachiasmatic nucleus receptors. It is also being studied for major depressive disorder and other circadian-related conditions.

Khối lượng phân tử

245,3200 g/mol

LogP

2,20

TPSA

38,30 Ų

Lipinski RO5

Đạt

Lĩnh vực điều trị

Insomnia Major Depressive Disorder

Cơ chế tác dụng

Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCC(=O)NC[C@@H]1C[C@H]1c1cccc2c1CCO2

                

                

                
                

                    
InChI

                    
InChI=1S/C15H19NO2/c1-2-15(17)16-9-10-8-13(10)11-4-3-5-14-12(11)6-7-18-14/h3-5,10,13H,2,6-9H2,1H3,(H,16,17)/t10-,13+/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C15H19NO2

                    

                    
                    

                        
HBD / HBA

                        
1 / 2

                    

                    
                    

                        
Liên kết có thể quay

                        
4

                    

                    
                    
                    

                        
Nguyên tử nặng

                        
18

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Câu hỏi thường gặp

                

                    
                    

                        
                        

                            
Tasimelteon is a selective melatonin receptor agonist (MT1 and MT2) approved for the treatment of non-24-hour sleep-wake disorder, a circadian rhythm disorder particularly prevalent in totally blind individuals without light perception. It synchronizes the circadian clock by mimicking the endogenous action of melatonin on suprachiasmatic nucleus receptors. It is also being studied for major depressive disorder and other circadian-related conditions.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Tasimelteon is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2103822.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 10220503.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Tuyên bố miễn trách y tế

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.